Fast Five Quiz: Overactive Bladder Pharmacologic Management

Bradley Schwartz, DO


February 26, 2021

According to the AUA/SUFU guidelines, ER formulations — if available — should preferentially be prescribed over IR formulations because of lower rates of dry mouth.

The guidelines state that because OAB is a chronic condition and treatment with antimuscarinics generally is required long-term, medication tolerability is critical to obtaining patient compliance. Adverse drug events, particularly dry mouth, are the major reasons that patients do not adhere with antimuscarinic therapy; thus, choosing the formulation with the lowest likelihood of adverse events may improve adherence. In addition, adherence with a once-daily treatment has been shown to be greater than with medications that are taken more than once a day.

The guidelines also note that if a patient has good symptom control and tolerable side effects on an IR formulation, then there is no need to change to an ER formulation.

Learn more about the pharmacologic management of OAB.

Editor's Recommendations


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.